Ulf Hannelius

Company: Diamyd Medical

Job title: President & Chief Executive Officer

Seminars:

Patient Identification for Clinical Trials – The Case of HLA & Antigen-Specific Immunotherapy in Type 1 Diabetes 9:30 am

• Retrospective and prospective clinical data show that individuals carrying HLA variants associated with autoimmunity against GAD (glutamic acid decarboxylase) respond to GAD-specific immunotherapy, supporting the notion of precision medicine in Type 1 diabetes • By prescreening for the presence of HLA DR3-DQ2, the HLA haplotype associated with GAD-specific autoimmunity, individuals that have a high…Read more

day: Day Two